#QGEN

5 days ago

QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System QIAGEN (NYSE: QGEN) received U.S. FDA clearance to run all QIAstat-Dx Gastrointestinal (GI) Panels on the fully automated QIAstat-Dx Rise platform, expanding the system's menu to consolidate respiratory and GI syndromic testing.The high-throughput Rise supports up to 160 tests per day, ~1-hour results and <1 minute hands-on time, and this marks the ninth FDA clearance for QIAstat-Dx in 24 months.

#QGEN QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System

www.stocktitan.net/news/QGEN/qiagen-receive...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028. VENLO, Netherlands---- QIAGEN N.V. today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and...

#QGEN QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth

www.stocktitan.net/news/QGEN/qiagen-sets-20...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million QIAGEN (NYSE: QGEN) will complete a synthetic share repurchase of approximately $500 million combining a direct capital repayment with a reverse stock split, effective with the last pre-consolidation trading day on January 7, 2026.Every 20 pre-consolidation shares will be consolidated into 19, reducing issued shares by about 10.9 million from 217.7 million, or roughly a 5% reduction. Following consolidation the company will repay $2.29 per pre-consolidation share from existing cash reserves. QIAGEN says this completes deliveries toward its commitment to return at least $1 billion to shareholders by end-2028 and that additional return measures are under consideration for 2026 and beyond.

#QGEN QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million

www.stocktitan.net/news/QGEN/qiagen-announc...

0 0 0 0

InsiderFinance

@insiderfinance.com

3 months ago

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CDZI 36.6x
2. #CVX 11.9x
3. #NFLX 6.9x
4. #QGEN 6.6x
5. #NNE 6.1x

#OptionFlow #OptionsTrading #Trading

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025 QIAGEN (NYSE: QGEN) introduced QIAsymphony Connect at AMP 2025 and began an early access program ahead of a planned full commercial release in mid-2026. The platform builds on >3,000 cumulative placements of the prior generation (end-2024) and promises improved extraction, up to 50% higher throughput in specific liquid biopsy protocols, 2D barcode traceability, LIMS and QIAsphere connectivity, and optimization for high-sensitivity oncology workflows like MRD monitoring.At AMP, QIAGEN highlighted Sample to Insight CGP workflows with Element Biosciences Trinity technology and a partnership with Myriad Genetics on an HRD assay; early-access data and planned commercial launches are targeted for early 2026 (commercial launch excluding Japan).

#QGEN QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025

www.stocktitan.net/news/QGEN/qiagen-unveils...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase QIAGEN (NYSE: QGEN) reported Q3 2025 net sales of $533 million (+6% at actual rates) and adjusted diluted EPS of $0.61, above its outlook. The company raised its FY2025 adjusted diluted EPS target to about $2.38 CER (from $2.35) and reaffirmed net sales growth of about 4–5% CER (core sales ~5–6% CER). Q3 adjusted operating income margin remained strong near 29.6% and operating cash flow was $165 million.QIAGEN announced the acquisition of Parse Biosciences to enter the single-cell market and approved a $500 million synthetic share repurchase to be completed in January 2026. The CEO will transition after a successor is appointed.

#QGEN QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase

www.stocktitan.net/news/QGEN/qiagen-exceeds...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions QIAGEN (NYSE: QGEN) will acquire Parse Biosciences to expand its Sample technologies into scalable single-cell solutions. QIAGEN will pay an upfront $225 million in cash, with up to $55 million in milestone payments; the deal is expected to close in December 2025. Parse brings Evercode instrument-free chemistry, the Tahoe-100M dataset (>100 million cells), GigaLab capacity of 2.5 billion cells/year, and use in >3,000 labs. Parse is expected to add ~$40 million revenue in 2026 (~2 percentage points growth) and to be dilutive ~$0.04 EPS in 2026, turning accretive in 2028.

#QGEN QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions

www.stocktitan.net/news/QGEN/qiagen-to-acqu...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

ArriTech Launches Next-Gen QGen Online for AI-Powered Compliance Solutions ArriTech unveils its QGen Online platform, combining AI-driven KYC, KYB, and AML solutions, helping businesses enhance onboarding efficiency and compliance.

ArriTech Launches Next-Gen QGen Online for AI-Powered Compliance Solutions #USA #Compliance #ArriTech #Floriana #QGen

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

ArriTech Unveils Next-Gen QGen Platform for No-Code KYC and AML Solutions with AI ArriTech has introduced QGen, a groundbreaking online platform enabling businesses to enhance compliance with KYC, KYB, and AML features using AI. Discover the future of onboarding with no-code solutions.

ArriTech Unveils Next-Gen QGen Platform for No-Code KYC and AML Solutions with AI #Malta #Compliance #ArriTech #Floriana #QGen

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing QIAGEN (NYSE: QGEN) has received FDA clearance for its QIAstat-Dx Rise, an enhanced version of its automated syndromic testing system. The new system offers significantly higher throughput, capable of processing up to 160 samples per day across eight analytical modules, including 16 batch samples and two urgent slots per run.The system features automated loading and unloading of cartridges, priority handling of urgent samples, and minimal hands-on time, delivering results in about one hour. Initially launching with Respiratory Panel Plus and Respiratory Panel Mini, QIAGEN plans to expand the test menu with gastrointestinal panels in the coming months. The QIAstat-Dx platform has already achieved significant market penetration with over 4,600 instruments placed globally through H1 2025 across more than 100 countries.

#QGEN QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

www.stocktitan.net/news/QGEN/qiagen-gains-u...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

$750 Million Bond Deal: QIAGEN Places Major Convertible Offering with Premium Conversion Terms QIAGEN announces $750M convertible bonds due 2032 with 2% annual coupon, 40% conversion premium. Semi-annual payments, net share settlement structure. 90-day company lock-up period.

#QGEN QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds

www.stocktitan.net/news/QGEN/qiagen-n-v-ann...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds QIAGEN (NYSE: QGEN) has announced plans to issue senior, unsecured net share settled convertible bonds due 2032. The offering, targeted at non-US institutional investors, will have an aggregate volume of USD 750 million with minimum denominations of USD 200,000 each.The bonds will have a 7-year maturity and feature an interest rate of 1.75% to 2.25% per annum, payable semi-annually. The conversion will involve approximately 11.2 million shares, representing about 5.1% of QIAGEN's current outstanding share capital. The initial conversion price will be set at a 40% to 45% premium over the reference share price.The settlement date is scheduled for September 4, 2025, and the bonds will be traded on the Open Market segment of the Frankfurt Stock Exchange. The proceeds will be used for general corporate purposes, including refinancing existing debt.

#QGEN QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds

www.stocktitan.net/news/QGEN/qiagen-n-v-lau...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels QIAGEN (NYSE: QGEN) has launched QIAseq xHYB Long Read Panels, a new suite of target enrichment solutions designed for long-read sequencing of complex genomic regions. The panels are optimized for native long-read platforms, including PacBio's technology, and aim to improve analysis of structural variants, HLA typing, and repeat expansions.Built on QIAGEN's hybrid-capture chemistry, the panels offer high target completeness, flexible formats including fixed panels for hereditary cancers and HLA typing, compatibility with high-molecular-weight DNA extraction kits, and integration with QIAGEN Digital Insights bioinformatics. The launch strengthens QIAGEN's position in providing solutions for both short- and long-read NGS technologies.

#QGEN #PACB QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

www.stocktitan.net/news/QGEN/qiagen-expands...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

QIAGEN's New Cancer Detection Breakthrough: Blood Test to Transform Solid Tumor Monitoring Groundbreaking partnership enables minimally invasive cancer monitoring using QIAcuity digital PCR platform. Discover how this changes tumor detection forever.

#QGEN Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

www.stocktitan.net/news/QGEN/tracer-biotech...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships QIAGEN (NYSE: QGEN) has announced two strategic partnerships to expand its minimal residual disease (MRD) testing capabilities in oncology. The company partnered with Tracer Biotechnologies to develop blood-based MRD tests for solid tumors using QIAcuity digital PCR systems, and with Foresight Diagnostics to create a kit version of its CLARITY™ NGS assay for lymphoma. These partnerships aim to advance decentralized, non-invasive tools for cancer monitoring and personalized treatment decisions. The collaborations will support pharmaceutical companies' clinical trials and companion diagnostic development. QIAGEN's comprehensive MRD portfolio includes sample technologies, testing platforms, and digital insights solutions, with plans to launch an upgraded QIAsymphony Connect version in late 2025.

#QGEN QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

www.stocktitan.net/news/QGEN/qiagen-expands...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma Foresight Diagnostics and QIAGEN (NYSE: QGEN) have announced a strategic worldwide partnership to develop and commercialize a kit version of Foresight's CLARITY™ assay for minimal residual disease (MRD) detection in lymphoma and other blood cancers. The collaboration combines Foresight's MRD detection technology with QIAGEN's global molecular diagnostic expertise. The partnership aims to create a standardized, regulated diagnostic kit that would be unique in offering both central laboratory service and diagnostic capabilities for ctDNA-based MRD testing. This kit, once validated and approved, will support clinical decision-making and therapeutic strategies for hematological cancer patients, enabling personalized treatment approaches through next-generation sequencing technology.

#QGEN Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma

www.stocktitan.net/news/QGEN/foresight-diag...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software QIAGEN (NYSE: QGEN) has announced the acquisition of Genoox for $70 million in cash, with potential additional milestone payments of up to $10 million. The acquisition brings Franklin, Genoox's AI-powered cloud platform for clinical decision support in genetic diseases, into QIAGEN's Digital Insights portfolio.Franklin is currently used by over 4,000 healthcare organizations across 50+ countries and has processed more than 750,000 case interpretations. The platform helps analyze next-generation sequencing (NGS) data and provides real-time, AI-driven insights for clinical decision-making in genetic disorders, cancer treatments, and family planning.The acquisition is expected to generate approximately $5 million in sales for 2025 with a neutral impact on adjusted EPS. QIAGEN plans to integrate its genomic content, including HGMD, COSMIC, and QKB databases, into the Franklin platform to enhance its interpretive capabilities.

#QGEN QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

www.stocktitan.net/news/QGEN/qiagen-enhance...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

QIAGEN Smashes Q1 Targets: 7% Growth Powers Confident 2025 Outlook Boost Strong Q1 performance drives QIAGEN to raise 2025 EPS guidance. QIAstat-Dx sales surge 35%, while QuantiFERON grows 15%. See full earnings analysis and growth drivers.

#QGEN QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

www.stocktitan.net/news/QGEN/qiagen-deliver...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook QIAGEN (NYSE:QGEN) reports strong preliminary Q1 2025 results, exceeding previous guidance. Net sales grew approximately 5% (+7% at constant exchange rates) to about $483 million, surpassing the outlook of 3% CER growth.The company's QuantiFERON latent TB test saw ~15% CER growth, while the QIAstat-Dx syndromic testing system advanced above 35% CER. The QIAcuity digital PCR system and QIAGEN Digital Insights both achieved high-single-digit CER gains. Sample technologies sales declined 1% CER due to cautious instrument spending among Life Sciences customers.QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to $2.35 CER from $2.28 CER, while maintaining its goal to improve adjusted operating income margin to above 30%. Q1 2025 adjusted diluted EPS is expected to be at least $0.55 CER, exceeding the previous outlook of $0.50 CER.

#QGEN QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook

www.stocktitan.net/news/QGEN/qiagen-n-v-qia...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

QIAGEN Releases Full 2024 Annual Report: Access Complete Financial Data and Analysis Access QIAGEN's comprehensive 2024 financial statements and annual report. Available online or in print format upon request. Get detailed insights.

#QGEN QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

www.stocktitan.net/news/QGEN/qiagen-announc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

How QIAGEN's Latest FDA Win Strengthens Its $4.6B Diagnostic Empire QIAGEN expands syndromic testing portfolio with rapid bacterial pathogen detection panel, marking its sixth regulatory clearance in 10 months and strengthening market position.

#QGEN QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

www.stocktitan.net/news/QGEN/qiagen-receive...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

How QIAGEN's Patent Lawsuit Against bioMérieux Could Reshape the TB Testing Market QIAGEN takes legal action to protect its WHO-endorsed QuantiFERON technology, following a previous successful patent defense against SD Biosensor.

#QGEN QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

www.stocktitan.net/news/QGEN/qiagen-takes-l...

0 0 0 0

Blue Wave 🌊 2026•2028🗽

@jmzmuda.bsky.social

1 year ago

#Doge doesn’t seem to understand that delaying/cutting #NIH funding to Universities not only hurts Unis & American lives, but also wallstreet. Cutting NIH research will impact biotech company revenue & thus their stock.
#TMO #NYSE #BDX #ILMN #A #TMO #BIO #RVTY #WAT #QGEN #DHR #BRKR #MTD #CZMWY

15 9 2 0

StockTitan

@stocktitan.net

1 year ago

Major Bioinformatics Milestone: QIAGEN's 8th Global Data Hub Powers Asia-Pacific Healthcare Revolution QIAGEN launches strategic Melbourne data center, expanding to 8 global facilities and enhancing genomic testing capabilities across Asia-Pacific region.

#QGEN QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

www.stocktitan.net/news/QGEN/qiagen-strengt...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

QIAGEN Earnings Triumph: Key Products Surge, Margins Expand as Cash Flow Hits Record QIAGEN delivers strong Q4 with $521M sales, beating outlook. Operating margin climbs to 30.6%, QIAstat-Dx and QuantiFERON show robust growth. 2025 outlook promises continued expansion.

#QGEN QIAGEN delivers solid Q4 2024 growth ahead of outlook

www.stocktitan.net/news/QGEN/qiagen-deliver...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Patent Victory: QIAGEN Secures Crucial TB Testing Technology Rights in Major Court Decision German Federal Patent Court upholds QIAGEN's QuantiFERON patent against SD Biosensor, reinforcing its position as global leader in tuberculosis detection technology.

#QGEN QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

www.stocktitan.net/news/QGEN/qiagen-receive...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

QIAGEN Announces $300M Share Repurchase Plan with Reverse Stock Split, $1.26 Per Share Payout QIAGEN unveils new synthetic share repurchase combining capital return and reverse stock split, marking second $300M buyback toward $1B shareholder return commitment by 2028.

#QGEN QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

www.stocktitan.net/news/QGEN/qiagen-announc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

QIAGEN Unveils New $300M Share Buyback Plan, Accelerating $1B Shareholder Return Strategy QIAGEN announces second $300M synthetic share repurchase program, fast-tracking its commitment to return $1B to shareholders by 2028 through innovative capital return method.

#QGEN QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

www.stocktitan.net/news/QGEN/qiagen-to-retu...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

QIAGEN Secures FDA Clearance for Groundbreaking Rapid Gastrointestinal Test Panel QIAGEN's new QIAstat-Dx panel delivers one-hour results for key gastrointestinal pathogens, becoming first company to offer both comprehensive and targeted testing solutions.

#QGEN QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

www.stocktitan.net/news/QGEN/qiagen-secures...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

QIAGEN Hits Major Milestone: 1,000+ EZ2 Connect Systems Deployed, Revolutionizing Lab Automation | QGEN Stock News QIAGEN achieves breakthrough milestone with EZ2 Connect, surpassing 1,000 placements. New PowerFecal Pro kit slashes processing time, advancing genomic research capabilities.

#QGEN QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

#StockMarket #investing #news

www.stocktitan.net/news/QGEN/qiagen-reaches...

0 0 0 0

Posts tagged #QGEN